$75.4 M

STSA Mkt cap, 23-Sept-2020
Satsuma Pharmaceuticals Net income (Q2, 2020)-11.3 M
Satsuma Pharmaceuticals EBIT (Q2, 2020)-11.5 M
Satsuma Pharmaceuticals Cash, 30-Jun-202032.1 M
Satsuma Pharmaceuticals EV47.2 M

Satsuma Pharmaceuticals Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

R&D expense

4.2m6.4m24.2m

General and administrative expense

754.0k1.1m4.7m

Operating expense total

4.9m7.5m28.9m

EBIT

(4.9m)(7.5m)(28.9m)

Interest expense

15.0k90.0k

Interest income

30.0k72.0k1.2m

Income tax expense

1.0k

Net Income

(5.2m)(7.3m)(28.2m)

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020

R&D expense

7.4m9.6m8.8m

General and administrative expense

1.0m2.5m2.7m

Operating expense total

8.5m12.2m11.5m

EBIT

(8.5m)(12.2m)(11.5m)

Interest income

331.0k502.0k325.0k

Income tax expense

Net Income

(8.3m)(11.8m)(11.3m)

Satsuma Pharmaceuticals Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

1.7m5.2m22.8m

Prepaid Expenses

256.0k199.0k7.0m

Current Assets

1.9m5.4m114.7m

PP&E

70.0k445.0k832.0k

Total Assets

2.0m6.4m126.3m

Accounts Payable

473.0k327.0k4.3m

Short-term debt

291.0k141.0k2.0m

Current Liabilities

1.7m2.0m8.0m

Long-term debt

4.8m3.0m

Total Debt

291.0k5.0m4.9m

Total Liabilities

1.9m6.9m10.9m

Common Stock

1.0k2.0k

Preferred Stock

5.5m11.6m

Additional Paid-in Capital

2.0m2.7m158.3m

Retained Earnings

(7.5m)(14.8m)(43.0m)

Total Equity

96.0k(484.0k)115.3m

Debt to Equity Ratio

3 x-10.3 x

Debt to Assets Ratio

0.1 x0.8 x

Financial Leverage

20.7 x-13.2 x1.1 x

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020

Cash

77.7m22.9m32.1m

Prepaid Expenses

7.6m8.1m7.0m

Current Assets

126.6m108.9m100.7m

PP&E

885.0k1.0m1.3m

Total Assets

127.5m113.7m102.6m

Accounts Payable

2.6m3.4m2.6m

Short-term debt

1.6m2.0m2.0m

Current Liabilities

5.9m7.2m6.7m

Long-term debt

3.4m2.5m2.0m

Total Debt

5.1m4.5m4.0m

Total Liabilities

9.4m9.7m8.7m

Common Stock

3.0k2.0k2.0k

Additional Paid-in Capital

150.3m158.8m159.7m

Retained Earnings

(32.2m)(54.8m)(66.0m)

Total Equity

118.1m104.0m93.9m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.1 x1.1 x

Satsuma Pharmaceuticals Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(5.2m)(7.3m)(28.2m)

Depreciation and Amortization

10.0k57.0k141.0k

Accounts Payable

363.0k(177.0k)4.0m

Cash From Operating Activities

(4.3m)(7.0m)(29.6m)

Purchases of PP&E

(58.0k)(402.0k)(551.0k)

Cash From Investing Activities

(58.0k)(402.0k)(95.9m)

Long-term Borrowings

(167.0k)

Cash From Financing Activities

10.9m143.1m

Net Change in Cash

(4.4m)3.5m17.6m

Interest Paid

34.0k347.0k

Income Taxes Paid

1.0k4.0k10.0k

Quarterly

USDQ3, 2019Q1, 2020Q2, 2020

Net Income

(17.4m)(11.8m)(23.0m)

Depreciation and Amortization

102.0k49.0k106.0k

Accounts Payable

1.4m(809.0k)(1.8m)

Cash From Operating Activities

(22.4m)(13.0m)(23.0m)

Purchases of PP&E

(463.0k)(283.0k)(487.0k)

Cash From Investing Activities

(41.8m)13.7m33.3m

Long-term Borrowings

(500.0k)(1.0m)

Cash From Financing Activities

136.7m(489.0k)(950.0k)

Net Change in Cash

72.5m148.0k9.4m

Interest Paid

265.0k77.0k152.0k

Income Taxes Paid

9.0k

Satsuma Pharmaceuticals Ratios

USDFY, 2017

Debt/Equity

3 x

Debt/Assets

0.1 x

Financial Leverage

20.7 x

Satsuma Pharmaceuticals Operating Metrics

Aug, 2019

Drugs in Development

37

Patents (Foreign)

9

Patents (US)

6